Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Horn

Internal Medicine Grand Rapids, MI Medical Doctor

NPI 1801843032 CMS profile 784774

4069 Lake Dr Se, Suite 113, Grand Rapids, MI 49546

Open in the dashboard

General payments

$4,476

240 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Horn of Grand Rapids, MI is reported in the CMS Open Payments database as having received $4,476 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,434 76
2024 General $1,054 54
2023 General $681 36
2022 General $659 35
2021 General $329 18
2020 General $156 11
2019 General $164 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Horn
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Benjamin Horn were reported at $1,434. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Benjamin Horn Internal Medicine median Middle half National median
2019 $164 $159 $48–$570 $163
2020 $156 $119 $33–$402 $114
2021 $329 $135 $37–$521 $132
2022 $659 $141 $42–$496 $149
2023 $681 $149 $45–$519 $160
2024 $1,054 $154 $47–$537 $164
2025 $1,434 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $825 42 payments
  2. AstraZeneca Pharmaceuticals LP $404 25 payments
  3. GlaxoSmithKline, LLC. $342 23 payments
  4. Pfizer Inc. $292 15 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $280 14 payments
  6. Novartis Pharmaceuticals Corporation $235 11 payments
  7. Amgen Inc. $163 9 payments
  8. Lilly USA, LLC $160 10 payments
  9. AbbVie, Inc. $158 7 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $155 9 payments
  11. Other $1,462 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,463 239 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Wegovy $408 21 payments
  2. Ozempic $350 17 payments
  3. RYBELSUS $350 17 payments
  4. TRELEGY ELLIPTA $274 18 payments
  5. NURTEC ODT $212 10 payments
  6. BREZTRI $174 10 payments
  7. Kerendia $155 9 payments
  8. JARDIANCE $154 8 payments
  9. ZAVZPRET $147 7 payments
  10. QULIPTA $134 6 payments
  11. Other $3,463 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,006

Median for Internal Medicine: 777

Drug cost

$37,135

Median for Internal Medicine: $73,373

Branded share of claims

5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 14 $22,015
Metoprolol Succinate Generic 67 $1,944
Rosuvastatin Calcium Generic 94 $1,687
Atorvastatin Calcium Generic 85 $1,384
Losartan Potassium Generic 55 $1,225
Levothyroxine Sodium Generic 71 $967
Celecoxib Generic 24 $690
Omeprazole Generic 37 $647
Ipratropium Bromide Generic 19 $613
Ezetimibe Generic 30 $609

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$11,297

Of which drugs: $2,578

Medicare patients

53

Average age 75

Services billed

192

12 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 40%
Ischemic heart disease 26%
Diabetes 25%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 16 16 $1,309

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $100
$100 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $66
  • Lilly USA, LLC $10
$76 — —
RYBELSUS
  • Novo Nordisk Inc $68
$68 — —
Ozempic
  • Novo Nordisk Inc $68
$68 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record